UNITY Biotechnology Announces Appointment of Federico Grossi, M.D., Ph.D., as Chief Medical Officer
UNITY Biotechnology [NASDAQ: UBX] has appointed Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings over 20 years of biotech industry experience, most recently serving as CMO at Apellis Pharmaceuticals where he led the development of SYFOVRE for geographic atrophy. His appointment comes at a important time as UNITY approaches the readout of topline 24-week results from its Phase 2b ASPIRE study of UBX1325 in diabetic macular edema (DME).
During his 13-year tenure at Apellis, Dr. Grossi oversaw clinical strategy and development programs across multiple therapeutic areas, leading to the approval and launch of EMPAVELI and SYFOVRE. He managed 10-15 concurrent studies from proof-of-concept through phase 3 clinical trials across global regions and built the medical affairs and safety functions.
UNITY Biotechnology [NASDAQ: UBX] ha nominato Federico Grossi, M.D., Ph.D., come direttore medico. Il Dr. Grossi porta con sé oltre 20 anni di esperienza nell'industria biotecnologica, avendo recentemente ricoperto il ruolo di CMO presso Apellis Pharmaceuticals, dove ha guidato lo sviluppo di SYFOVRE per l'atrofia geografica. La sua nomina avviene in un momento importante, poiché UNITY si avvicina alla pubblicazione dei risultati preliminari a 24 settimane dello studio di Fase 2b ASPIRE su UBX1325 nel trattamento dell'edema maculare diabetico (DME).
Durante il suo mandato di 13 anni in Apellis, il Dr. Grossi ha supervisionato la strategia clinica e i programmi di sviluppo in diversi ambiti terapeutici, portando all'approvazione e al lancio di EMPAVELI e SYFOVRE. Ha gestito 10-15 studi contemporanei, dalla prova del concetto fino agli studi clinici di fase 3 in diverse regioni globali, e ha costruito le funzioni di affari medici e sicurezza.
UNITY Biotechnology [NASDAQ: UBX] ha nombrado a Federico Grossi, M.D., Ph.D., como director médico. El Dr. Grossi aporta más de 20 años de experiencia en la industria biotecnológica, habiendo servido más recientemente como CMO en Apellis Pharmaceuticals, donde lideró el desarrollo de SYFOVRE para la atrofia geográfica. Su nombramiento llega en un momento importante, ya que UNITY se acerca a la lectura de los resultados preliminares de 24 semanas del estudio de Fase 2b ASPIRE de UBX1325 en el edema macular diabético (DME).
Durante su mandato de 13 años en Apellis, el Dr. Grossi supervisó la estrategia clínica y los programas de desarrollo en múltiples áreas terapéuticas, lo que llevó a la aprobación y el lanzamiento de EMPAVELI y SYFOVRE. Gestionó de 10 a 15 estudios simultáneos desde la prueba de concepto hasta los ensayos clínicos de fase 3 en diversas regiones del mundo y construyó las funciones de asuntos médicos y seguridad.
UNITY Biotechnology [NASDAQ: UBX]는 Federico Grossi, M.D., Ph.D.를 최고 의료 책임자로 임명했습니다. Grossi 박사는 최근 Apellis Pharmaceuticals의 CMO로 재직하며 지리적 위축을 치료하기 위한 SYFOVRE 개발을 이끌어온 20년 이상의 생명공학 산업 경험을 갖고 있습니다. 그의 임명은 UNITY가 당뇨병성 황반부종(DME)에 대한 UBX1325의 24주 결과 발표를 앞두고 있는 중요한 시점에 이루어졌습니다.
Apellis에서 13년 동안 재직하는 동안 Grossi 박사는 여러 치료 분야에서 임상 전략 및 개발 프로그램을 감독하며 EMPAVELI와 SYFOVRE의 승인 및 출시를 이끌었습니다. 그는 개념 증명부터 3상 임상 시험까지 10~15개의 동시 연구를 관리하고, 의학적 업무와 안전 기능을 구축했습니다.
UNITY Biotechnology [NASDAQ: UBX] a nommé Federico Grossi, M.D., Ph.D. au poste de directeur médical. Le Dr Grossi apporte plus de 20 ans d'expérience dans l'industrie biotechnologique, ayant récemment occupé le poste de CMO chez Apellis Pharmaceuticals, où il a dirigé le développement de SYFOVRE pour l'atrophie géographique. Sa nomination survient à un moment important, alors que UNITY s'apprête à publier les résultats préliminaires à 24 semaines de son étude de Phase 2b ASPIRE sur UBX1325 dans le cadre de l'œdème maculaire diabétique (DME).
Au cours de ses 13 années chez Apellis, le Dr Grossi a supervisé la stratégie clinique et les programmes de développement dans plusieurs domaines thérapeutiques, ce qui a conduit à l'approbation et au lancement d'EMPAVELI et SYFOVRE. Il a géré de 10 à 15 études simultanées, allant des preuves de concept aux essais cliniques de phase 3 dans diverses régions du monde, et a développé les fonctions liées aux affaires médicales et à la sécurité.
UNITY Biotechnology [NASDAQ: UBX] hat Federico Grossi, M.D., Ph.D. zum Chief Medical Officer ernannt. Dr. Grossi bringt über 20 Jahre Erfahrung in der Biotechnologiebranche mit und war zuletzt CMO bei Apellis Pharmaceuticals, wo er die Entwicklung von SYFOVRE zur Behandlung von geografischer Atrophie leitete. Seine Ernennung kommt zu einem wichtigen Zeitpunkt, da UNITY sich der Bekanntgabe der vorläufigen 24-Wochen-Ergebnisse seiner Phase 2b ASPIRE-Studie zu UBX1325 bei diabetischem Makulaödem (DME) nähert.
Während seiner 13-jährigen Amtszeit bei Apellis überwachte Dr. Grossi die klinische Strategie und Entwicklungsprogramme in mehreren Therapiebereichen, was zur Genehmigung und Markteinführung von EMPAVELI und SYFOVRE führte. Er leitete 10-15 gleichzeitige Studien von der Proof-of-Concept-Phase bis zu klinischen Studien der Phase 3 in verschiedenen globalen Regionen und baute die medizinische und sicherheitstechnische Abteilungen auf.
- Appointment of experienced CMO with successful track record in ophthalmology drug development
- New CMO led development and approval of two commercial products (SYFOVRE and EMPAVELI)
- Timing aligns with upcoming Phase 2b ASPIRE trial results for UBX1325
- None.
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and regulatory strategy in ophthalmology and other indications, most recently having led the development of SYFOVRE for geographic atrophy as chief medical officer at Apellis Pharmaceuticals.
“Dr. Grossi’s extensive experience in clinical strategy and a successful track record of advancing novel ophthalmology programs from inception through approval and commercial launch make him an exceptional fit for our team,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. “Additionally, Dr. Grossi’s impressive experience navigating the regulatory pathway for novel treatments is timely as he steps into this role on the cusp of our key data readout of topline 24-week results from our Phase 2b ASPIRE study of UBX1325 in diabetic macular edema (DME). I am confident that his leadership will support our strategic vision and accelerate our efforts to deliver a new class of therapeutics that potentially restores diseased tissue to a healthier state and could provide long-lasting, disease-modifying benefits.”
Dr. Grossi brings over 20 years of experience working in the biotech industry, including R&D strategy, clinical trial design, organizational build and executive management. Notably, he served as the chief medical officer of Apellis Pharmaceuticals, a global biopharmaceutical company focused on developing life-changing therapies in serious retinal and rare diseases. Dr. Grossi oversaw the clinical strategy and development programs in ophthalmology, hematology, neurology and nephrology, leading to the approval and commercial launch of EMPAVELI (paroxysmal nocturnal hemoglobinuria) and SYFOVRE (geographic atrophy). Over his 13-year tenure at Apellis in various roles of increasing leadership, he was responsible for all clinical development activities including 10-15 concurrent studies from proof-of-concept through phase 3 clinical trials across the U.S., Europe, Latin America and Asia-Pacific regions, established the medical affairs and safety and pharmacovigilance functions and exponentially expanded the team to build a high-performing organization. Dr. Grossi earned his M.D. at the Universidad Nacional de Córdoba in Argentina, as well as M.S. and Ph.D. degrees in physiology and biophysics at the University of Louisville.
“I am thrilled to join UNITY at this critical juncture in the clinical development of UBX1325 and help realize the transformative potential of senolytic treatments for retinal diseases,” said Dr. Grossi. “I look forward to working closely with the team to advance UBX1325, deliver on our upcoming Phase 2b ASPIRE clinical trial data in diabetic macular edema, and advance our pipeline to provide new and differentiated treatment options for patients with progressive retinal diseases.”
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME and other ophthalmologic diseases, and the expected timing of results of the clinical trial in UBX1325. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks related to delay or disruption in clinical trials, risks relating to the uncertainties inherent in the drug development process, and risks relating to UNITY’s understanding of senescence biology. The Company may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general and the sufficiency of its cash runway, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission on November 4, 2024, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.
Media Contact
Inizio Evoke Comms
Katherine Smith
Katherine.Smith@inizioevoke.com
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com
FAQ
When will UNITY Biotechnology release Phase 2b ASPIRE trial results for UBX1325?
What experience does UBX's new Chief Medical Officer bring to the company?
What is the main drug candidate being developed by UNITY Biotechnology (UBX)?
What therapeutic areas does UBX focus on?
